Novo Nordisk
Research Novo Nordisk (NVO) on Bullrun: valuation model: 20.7% undervalued, market cap USD 214.14B, P/E 11.3, dividend yield 2.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNVO
- ExchangeNYSE
- CountryDenmark
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal20.7% undervalued
- Market capUSD 214.14B
- P/E11.3
- Dividend yield2.6%
- Financial periodQ1 2026
- RevenueUSD 96.82B
- Net incomeUSD 48.56B
- Free cash flowUSD 12.05B
- Gross margin86.0%
Valuation Snapshot
Bullrun's latest valuation model marks Novo Nordisk as 20.7% undervalued; latest market cap is USD 214.14B; P/E is 11.3; dividend yield is 2.6%.
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
Frequently asked questions
Is Novo Nordisk overvalued or undervalued?
Bullrun's valuation model currently marks Novo Nordisk as 20.7% undervalued.
What is Novo Nordisk's market cap?
Novo Nordisk's market capitalization is USD 214.14B.
What is Novo Nordisk's P/E ratio?
Novo Nordisk's price-to-earnings (P/E) ratio is 11.3.
Does Novo Nordisk pay a dividend?
Novo Nordisk has a dividend yield of 2.6%.
What does Novo Nordisk do?
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.